Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Spectral Medical Inc T.EDT

Alternate Symbol(s):  EDTXF

Healthcare Biotechnology Medical Instruments & Supplies
Spectral Medical Inc. is a Canada-based late-stage theragnostic company advancing therapeutic options for sepsis and septic shock. The Company develops and commercializes a treatment for septic shock utilizing its Endotoxin Activity Assay (EAA) diagnostic and the Toraymyxin therapeutic (PMX). PMX is a therapeutic hemoperfusion device that removes endotoxin, which can cause sepsis, from the bloodstream and is guided by the Company’s EAA. PMX is approved for therapeutic use in Japan and Europe and has been used safely and effectively on more than 340,000 patients to date. It has pioneered the development of biochemical markers for the clinical syndrome known as septic shock. It is continuing its legacy business of manufacturing and selling certain proprietary reagents. It develops, produces and markets recombinant proteins, antibodies and calibrators. These materials are sold for use in research and development, as well as in products manufactured by other diagnostic companies.


TSX:EDT - Post by User

Spectral Medical Inc > Secondary infections - Covid -19
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(800)
•••
Comment by SouthernTierTomon Jan 12, 2021 10:25pm
194 Views
Post# 32282509

RE:RE:Secondary infections - Covid -19

RE:RE:Secondary infections - Covid -19Thanks for the math...whilst we compare our value to other true "start-ups" in the Canadien bio-game...it would appear we are severely undervalued or others are laughably over-valued...I've always been a "sister golden hare" kind of person..."meat me in the middle" type...at 79 MILLION USD we seem like good value...

Canadian OTC SONA, a covid19 rabbit has failed FDA approval and been rejected by Canada Health..yet it reached 800 MILLION ...all for a questionable CV19 diagnostic...Hmmmmmm

The head of marketing seemed reluctant to buy in to these "Canadien High Flyers"...but they are real...TRIL at 1.8 BILLION, Mindmed, the LSD start-up at 1.5 BILLION...

EDT has room to move...before it even leaves the station - IMHO
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities